Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8MJ3F)

Drug Name

PB1046 Drug Info

Synonyms

Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera

Indication

Disease Entry	ICD 11	Status	REF
Heart failure	BD10-BD13	Phase 2	[1]
Pulmonary arterial hypertension	BB01.0	Phase 2	[2]
Cardiomyopathy	BC43	Phase 1	[3]
Duchenne dystrophy	8C70	Phase 1	[1]
Hypertension	BA00-BA04	Phase 1	[4]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Helodermin-preferring VIP receptor (VIPR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG-7103	DM2IDQ9	Chronic obstructive pulmonary disease	CA22	Phase 1	[6]
PACAP-27	DMB26IK	Discovery agent	N.A.	Investigative	[7]
helodermin	DMIUABO	Discovery agent	N.A.	Investigative	[8]
PB-1120	DMX7WU9	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Helodermin-preferring VIP receptor (VIPR2)	TT4O5P0	VIPR2_HUMAN	Agonist	[5]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT03795428) Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (VIP Extend). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of PhaseBio.
5	Clinical pipeline report, company report or official report of PhaseBio Pharmaceuticals.
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027925)
7	A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology. 2006 Nov;51(6):1086-98.
8	Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors. Ann N Y Acad Sci. 1998 Dec 11;865:247-52.
9	Company report (PhaseBio)